Abstract Number: 0356 • ACR Convergence 2024
Patient Satisfaction and Experience After a Switch to a Citrate-free High-concentration Adalimumab Biosimilar. Results from a Prospective Multicentric Real-world Study
Background/Purpose: Biosimilars (BioS) are cost-effective alternatives to reference products for patients with chronic inflammatory rheumatic diseases (CIRD) and inflammatory bowel diseases (IBD), but treatment adherence…Abstract Number: 1452 • ACR Convergence 2024
Assessing Responsiveness of Outcome Measures for Children with Axial Juvenile Spondyloarthritis (JSpA)
Background/Purpose: Trials for patients with juvenile spondyloarthritis (JSpA) and axial disease are scarce. We assessed the responsiveness of measures for use in trials of patients…Abstract Number: 2619 • ACR Convergence 2024
Safety Outcomes of Routine Blood Tests for Monitoring of Biologic and Targeted Synthetic Therapies in Inflammatory Arthritis Patients
Background/Purpose: Patients treated with biologic or targeted synthetic (b/ts) DMARDs are recommended to perform safety blood monitoring every 3 months in the absence of strong…Abstract Number: 0363 • ACR Convergence 2024
Comparative Risk of Demyelinating Diseases Among Patients on TNF-Alpha Inhibitors: A Cohort Study Using the TriNetX Database
Background/Purpose: TNF-alpha inhibitors are widely used in the field of rheumatology and have been linked to various possible adverse events, including demyelinating diseases. This association…Abstract Number: 1679 • ACR Convergence 2024
Differential Pharmacodynamic Changes of Circulated Immune Subsets After Treatment with Abatacept or Adalimumab in Patients with ACPA+ Early RA in the AMPLIFIED Study
Background/Purpose: Despite considerable advances in pharmacologic approaches to RA management, a better understanding of the underlying immunopathology is still needed.1,2 A dysregulated immune system is…Abstract Number: 0465 • ACR Convergence 2024
Therapeutic Drug Monitoring of the Adalimumab Biosimilar (AMJEVITA™, Adalimumab-atto) Using Originator Adalimumab and Anti-Adalimumab Antibody Assays
Background/Purpose: Treatment of RA with biologic TNF inhibitors is effective in reducing disease activity and improving radiographic progression outcomes. Therapeutic drug monitoring (TDM) of adalimumab…Abstract Number: 1850 • ACR Convergence 2024
Exhausted T-cells Are Increased in Autoimmune Diseases and Predict Response to Anti-TNF in RA and SPA Patients
Background/Purpose: Exhaustion can occur after prolonged activation of T cells limiting their immunosurveillance function leading to cancer emergence. Among the exhaustion markers expressed on T…Abstract Number: 0519 • ACR Convergence 2024
Comparable Malignancy Risk of Janus Kinase Inhibitors with Conventional Synthetic and Biologic DMARDs in Asian Patients with Rheumatoid Arthritis: A Comprehensive Analysis from Two Medical Centers
Background/Purpose: JAK inhibitors (JAKi) and biologic disease-modifying antirheumatic drugs (bDMARDs) have proven efficacy in the treatment of rheumatoid arthritis (RA). However, their potential for increasing…Abstract Number: 1892 • ACR Convergence 2024
Early Tumor Necrosis Factor Inhibitor Initiation and Chronic Opioid Use in Individuals with Axial Spondyloarthritis
Background/Purpose: Patients with axial spondyloarthritis (axSpA) bear a substantial burden of chronic opioid use despite the availability of effective treatments like tumor necrosis factor inhibitors…Abstract Number: 0523 • ACR Convergence 2024
Distinct Peripheral Blood Immune Cell Sub-population Signatures at Baseline of Tofacitinib or Adalimumab Initiation Are Associated to Clinical Responses at 6 Months
Background/Purpose: Biomarkers to predict response to tofacitinib or adalimumab are not clinically available. Herein we aimed to characterize peripheral blood immune cell subsets with a…Abstract Number: 1959 • ACR Convergence 2024
A 3-arm, Randomized, Open-label, Parallel Active Controlled, Multicentre International Study to Compare the Response of Ultrasound-assessed Synovitis to Baricitinib, Alone and Combined with Methotrexate versus Etanercept in Rheumatoid Arthritis Patients
Background/Purpose: To demonstrate non-inferiority of the response of musculoskeletal ultrasound (MSKUS)-assessed synovitis to baricitinib, alone and plus MTX vs. etanercept plus MTX in patients with…Abstract Number: 0586 • ACR Convergence 2024
Real World Effectiveness of Upadacitinib in Patients with Psoriatic Arthritis Previously Treated with TNF Inhibitors: Data from the OM1 Registry
Background/Purpose: Upadacitinib (UPA), an oral JAK inhibitor, has demonstrated efficacy for the treatment of PsA in randomized controlled trials of patients with inadequate response or…Abstract Number: 2253 • ACR Convergence 2024
A Phase 1 Single Ascending Dose Study to Evaluate the Safety and Pharmacokinetics of ZB002, an Anti-TNFα mAb Designed for Extended Half-life, in Healthy Volunteers
Background/Purpose: ZB002 is a recombinant human monoclonal antibody (mAb) that targets human TNFα with an Fv domain identical in amino acid sequence to adalimumab and…Abstract Number: 0595 • ACR Convergence 2024
bDMARD Drug Survival in Combination Therapy with Methotrexate in Psoriatic Arthritis: A Systematic Literature Review and Meta-analysis
Background/Purpose: During the last two decades we’ve witnessed the rising use of biologic disease-modifying antirheumatic drugs (bDMARDs) in the treatment of psoriatic arthritis (PsA), leaving…Abstract Number: 2269 • ACR Convergence 2024
Adalimumab Dose Reduction Using Therapeutic Drug Monitoring to Manage Low Disease Activity in Rheumatoid Arthritis: A Single-Blind, Non-Inferiority, Randomized Clinical Trial
Background/Purpose: The latest European and American recommendations support tapering of biological DMARDs (bDMARDs) in patients with persistent remission or low disease activity. Most clinicians use…
- 1
- 2
- 3
- …
- 18
- Next Page »